NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RYTM

*Your capital is at risk

$106.60

+0.510 (+0.481%)

At Close: Jul 17, 2026

Rhythm Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 2.37. In total, the insiders bought 811.94K and sold 82.15K RYTM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	2.37
● Buy	811.94K shares
● Sell	82.15K shares
71% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Jun 24, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 11, 2026 Buy	Stock Options (Right to Buy) A-Award	Garfield Alastair Chief Scientific Officer	Officer	25 000 Value: $2.46M
Feb 11, 2026 Buy	Restricted Stock Units A-Award	Garfield Alastair Chief Scientific Officer	Officer	16 650 Value: $1.64M
Feb 11, 2026 Buy	Stock Options (Right to Buy) A-Award	Cramer Pamela J. Chief Human Resources Officer	Officer	17 500 Value: $1.72M
Feb 11, 2026 Buy	Restricted Stock Units A-Award	Cramer Pamela J. Chief Human Resources Officer	Officer	11 650 Value: $1.15M
Feb 11, 2026 Buy	Restricted Stock Units A-Award	Smith Hunter C Chief Financial Officer	C-Suite Officer	25 000 Value: $2.46M
Feb 11, 2026 Buy	Stock Options (Right to Buy) A-Award	Smith Hunter C Chief Financial Officer	C-Suite Officer	37 500 Value: $3.69M
Feb 11, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	100 Value: $10.1K
Feb 11, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	400 Value: $39.8K
Feb 11, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	2 266 Value: $222.9K
Feb 10, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	1 913 Value: $196.4K
Feb 10, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	700 Value: $72.6K
Feb 10, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	100 Value: $10.5K
Feb 05, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	3 381 Value: $358.6K
Feb 04, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	1 500 Value: $157.1K
Feb 04, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	1 000 Value: $106.6K
Feb 04, 2026 Sell	Common Stock S-Sale	Smith Hunter C Chief Financial Officer	C-Suite Officer	747 Value: $80.4K
Feb 01, 2026 Buy	Common Stock M-Exempt	Shulman Joseph Chief Technical Officer	Officer	16 968 Value: $1.81M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	4 062 Value: $433.0K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	4 925 Value: $525.0K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	6 600 Value: $703.6K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	10 413 Value: $1.11M
Feb 01, 2026 Sell	Common Stock F-InKind	Smith Hunter C Chief Financial Officer	C-Suite Officer	10 750 Value: $1.17M
Feb 01, 2026 Buy	Common Stock M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	26 000 Value: $2.77M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	5 500 Value: $586.3K
Feb 01, 2026 Buy	Common Stock M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	5 500 Value: $586.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström s...

Read Full Profile Here